Invitae (NYSE:NVTA) Trading Down 5.1%
Invitae (NYSE:NVTA) Trading Down 5.1%
Invitae Co. (NYSE:NVTA – Get Rating)'s stock price fell 5.1% during mid-day trading on Friday . The company traded as low as $2.78 and last traded at $2.82. 37,359 shares were traded during mid-day trading, a decline of 100% from the average session volume of 9,110,689 shares. The stock had previously closed at $2.97.
Invitae Co.(紐約證券交易所代碼：NVTA-GET Rating)股價週五午盤下跌5.1%。該公司股價最低跌至2.78美元，最新報2.82美元。午盤成交量為37,359股，較9,110,689股的平均成交量下降100%。該股此前收盤價為2.97美元。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of equities analysts have weighed in on NVTA shares. William Blair reissued a "market perform" rating on shares of Invitae in a research note on Tuesday, November 8th. Cowen lifted their target price on Invitae to $2.80 in a research report on Tuesday, November 15th. Credit Suisse Group initiated coverage on Invitae in a research report on Wednesday, August 24th. They issued an "underperform" rating on the stock. JPMorgan Chase & Co. downgraded Invitae from a "neutral" rating to an "underweight" rating in a research report on Wednesday, August 10th. Finally, SVB Leerink lifted their target price on Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a research report on Wednesday, November 9th. Four equities research analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.04.
許多股票分析師對NVTA的股票進行了加碼。11月8日，威廉·布萊爾在一份研究報告中重新發布了對Invitae股票的“市場表現”評級。考恩在11月15日週二的一份研究報告中將Invitae的目標價上調至2.80美元。瑞士信貸集團在8月24日星期三的一份研究報告中啟動了對Invitae的報道。他們對該股給予了“表現不佳”的評級。摩根大通在8月10日週三的一份研究報告中將Invitae的評級從中性下調至減持。最後，SVB Leerink在11月9日(週三)的一份研究報告中將Invitae的目標價從2.50美元上調至3.00美元，並給予該公司“市場表現”評級。4名股票研究分析師對該股的評級為賣出，9名分析師對該公司的評級為持有。根據MarketBeat的數據，該公司的共識評級為持有，共識目標價為8.04美元。
Invitae Price Performance
Invitae性價比
The stock has a market capitalization of $689.84 million, a price-to-earnings ratio of -0.21 and a beta of 1.61. The company has a debt-to-equity ratio of 10.03, a quick ratio of 6.18 and a current ratio of 6.44. The company has a 50 day moving average of $2.58 and a 200 day moving average of $2.87.
該股市值為6.894億美元，市盈率為-0.21倍，貝塔係數為1.61。該公司的負債權益比率為10.03，速動比率為6.18，流動比率為6.44。該公司的50日移動均線切入位在2.58美元，200日移動均線切入位在2.87美元。
Institutional Trading of Invitae
Invitae的制度性交易
A number of large investors have recently made changes to their positions in the company. ARK Investment Management LLC boosted its position in shares of Invitae by 6.3% in the 3rd quarter. ARK Investment Management LLC now owns 30,468,381 shares of the medical research company's stock valued at $74,952,000 after purchasing an additional 1,799,431 shares during the period. Vanguard Group Inc. raised its stake in Invitae by 2.6% during the 3rd quarter. Vanguard Group Inc. now owns 21,624,354 shares of the medical research company's stock valued at $53,196,000 after acquiring an additional 544,941 shares during the last quarter. Rock Springs Capital Management LP raised its stake in Invitae by 18.7% during the 1st quarter. Rock Springs Capital Management LP now owns 3,323,821 shares of the medical research company's stock valued at $26,491,000 after acquiring an additional 523,578 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Invitae by 34.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 2,551,464 shares of the medical research company's stock valued at $6,226,000 after acquiring an additional 647,362 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Invitae by 11.8% during the 2nd quarter. Northern Trust Corp now owns 2,132,881 shares of the medical research company's stock valued at $5,204,000 after acquiring an additional 225,589 shares during the last quarter. 88.27% of the stock is owned by institutional investors and hedge funds.
一些大型投資者最近對他們在該公司的頭寸進行了調整。方舟投資管理有限責任公司在第三季度將其在Invitae股票的頭寸增加了6.3%。方舟投資管理公司現在擁有30,468,381股這家醫療研究公司的股票，價值74,952,000美元，在此期間又購買了1,799,431股。先鋒集團(Vanguard Group Inc.)第三季度增持Invitae股份2.6%。先鋒集團(Vanguard Group Inc.)在上個季度增持了544,941股後，目前持有這家醫療研究公司21,624,354股票，價值53,196,000美元。Rock Springs Capital Management LP在第一季度將其在Invitae的持股增加了18.7%。Rock Springs Capital Management LP在上個季度增持了523,578股票後，現在擁有這家醫療研究公司3,323,821股票，價值26,491,000美元。高盛股份有限公司在第二季度增持了Invitae 34.0%的股份。高盛股份有限公司在上個季度增持了647,362股後，目前持有這家醫學研究公司2,551,464股股票，價值6,226,000美元。最後，北方信託公司在第二季度將其在Invitae的持股比例提高了11.8%。Northern Trust Corp目前持有這家醫療研究公司2,132,881股股票，價值5,204,000美元，此前該公司在上個季度又收購了225,589股。88.27%的股票由機構投資者和對衝基金持有。
Invitae Company Profile
Invitae公司簡介
(Get Rating)
(獲取評級)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Invitae公司是一家醫學遺傳學公司，將遺傳信息整合到主流醫學中，以改善美國、加拿大和國際上人們的醫療保健。該公司提供各種臨牀領域的基因測試，包括遺傳癌、心臟病學、神經病學、兒科、腫瘤學、代謝疾病和罕見疾病；數字健康解決方案；以及健康數據服務。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免費獲取StockNews.com關於Invitae的研究報告(NVTA)
- 為什麼CSL有限公司的股票值得一看
- MarketBeat：回顧一週11/28-12/02
- Okta Inc.慶祝收益節節攀升，但他們能持續這種提振嗎？
- 機構正在購買安巴雷拉，你應該嗎？
- ZIM能否抵禦集裝箱航運業的普遍低迷？
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
接受《邀請日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Invitae和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。